STOK Stock Analysis: Buy, Sell, or Hold?
STOK - Stoke Therapeutics, Inc. Common Stock
$31.99
-0.57 (-1.75%)
▼
5d:
-5.33%
30d:
-5.3%
90d:
+0.53%
HOLD
LOW Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
STOK is down 4.8% this week, but smart money is accumulating calls. Top strike: $35 2026-05-15 with 84 OI. Call ratio: 93% View Scanner →
Strength: 6.7/10
Get Alerted When STOK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: STOK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: STOK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: STOK is currently trading at $31.99, which is considered fair relative to its 30-day fair value range of $32.53 to $36.53.
Technical Outlook: Technically, STOK is in a strong uptrend. Immediate support is located at $29.86, while resistance sits at $35.29.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $45.10 (+41.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, STOK is in a strong uptrend. Immediate support is located at $29.86, while resistance sits at $35.29.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $45.10 (+41.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$32.53 -
$36.53
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
Protect Your Profits
Holding STOK? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 41.0% below Wall St target ($45.10)
- CAUTION: Recommendation downgraded due to -5.3% 5-day decline
Fair Price Analysis
30-Day Fair Range
$32.53 -
$36.53
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$29.86
Resistance Level
$35.29
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.07
Wall Street Target
$45.10
(+41.0%)
Revenue Growth (YoY)
-93.8%
Profit Margin
-3.7%
Share & Embed Analysis
Last updated: April 02, 2026 6:05 AM ET
Data refreshes hourly during market hours. Next update: 7:05 AM
Data refreshes hourly during market hours. Next update: 7:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is STOK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Arthur A Levin
SELL
605 shares
2026-03-13
Adrian R Krainer
SELL
33243 shares
2026-03-10
Arthur Tzianabos
SELL
4355 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 66 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 65 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 62 BUY |
Advanced STOK Option Strategies
Professional options setups generated by AI based on today's STOK price and gamma walls.
